Titre : Inducteurs du cytochrome P-450 CYP2C9

Inducteurs du cytochrome P-450 CYP2C9 : Questions médicales fréquentes

Termes MeSH sélectionnés :

Recovery of Function
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Inducteurs du cytochrome P-450 CYP2C9 : Questions médicales les plus fréquentes", "headline": "Inducteurs du cytochrome P-450 CYP2C9 : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Inducteurs du cytochrome P-450 CYP2C9 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-01-07", "dateModified": "2025-04-01", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Inducteurs du cytochrome P-450 CYP2C9" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Inducteurs des enzymes du cytochrome P-450", "url": "https://questionsmedicales.fr/mesh/D065693", "about": { "@type": "MedicalCondition", "name": "Inducteurs des enzymes du cytochrome P-450", "code": { "@type": "MedicalCode", "code": "D065693", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D27.505.519.349" } } }, "about": { "@type": "MedicalCondition", "name": "Inducteurs du cytochrome P-450 CYP2C9", "alternateName": "Cytochrome P-450 CYP2C9 Inducers", "code": { "@type": "MedicalCode", "code": "D065698", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Miklós Poór", "url": "https://questionsmedicales.fr/author/Mikl%C3%B3s%20Po%C3%B3r", "affiliation": { "@type": "Organization", "name": "Department of Pharmacology, Faculty of Pharmacy, University of Pécs, Rókus u. 2, Pécs H-7624, Hungary; Lab-on-a-Chip Research Group, János Szentágothai Research Centre, University of Pécs, Ifjúság útja 20, Pécs H-7624, Hungary. Electronic address: poor.miklos@pte.hu." } }, { "@type": "Person", "name": "Jian-Ping Cai", "url": "https://questionsmedicales.fr/author/Jian-Ping%20Cai", "affiliation": { "@type": "Organization", "name": "The Key laboratory of Geriatrics, Beijing Institute of Geriatrics, Beijing Hospital, National Center of Gerontology, National Health Commission, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, P. R. China." } }, { "@type": "Person", "name": "Slávka Bodnárová", "url": "https://questionsmedicales.fr/author/Sl%C3%A1vka%20Bodn%C3%A1rov%C3%A1", "affiliation": { "@type": "Organization", "name": "Department of Pharmacology, Faculty of Pharmacy, University of Pécs, Rókus u. 2, Pécs H-7624, Hungary; Lab-on-a-Chip Research Group, János Szentágothai Research Centre, University of Pécs, Ifjúság útja 20, Pécs H-7624, Hungary." } }, { "@type": "Person", "name": "Eszter Fliszár-Nyúl", "url": "https://questionsmedicales.fr/author/Eszter%20Flisz%C3%A1r-Ny%C3%BAl", "affiliation": { "@type": "Organization", "name": "Department of Pharmacology, Faculty of Pharmacy, University of Pécs, Rókus u. 2, Pécs H-7624, Hungary; Lab-on-a-Chip Research Group, János Szentágothai Research Centre, University of Pécs, Ifjúság útja 20, Pécs H-7624, Hungary." } }, { "@type": "Person", "name": "Jian Liu", "url": "https://questionsmedicales.fr/author/Jian%20Liu", "affiliation": { "@type": "Organization", "name": "The Key laboratory of Geriatrics, Beijing Institute of Geriatrics, Beijing Hospital, National Center of Gerontology, National Health Commission, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, P. R. China." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "The impact of perceived and internalised stigma on clinical and functional recovery among people with mental illness.", "datePublished": "2022-10-18", "url": "https://questionsmedicales.fr/article/36254881", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/hsc.14047" } }, { "@type": "ScholarlyArticle", "name": "Hand Therapy Regimen for Functional Recovery Following Combined Face and Bilateral Hand Transplantation.", "datePublished": "2022-10-08", "url": "https://questionsmedicales.fr/article/36214276", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1177/15589447221124250" } }, { "@type": "ScholarlyArticle", "name": "Potentially inappropriate medications are negatively associated with functional recovery in patients with sarcopenia after stroke.", "datePublished": "2022-08-29", "url": "https://questionsmedicales.fr/article/36038811", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s40520-022-02224-7" } }, { "@type": "ScholarlyArticle", "name": "Tailoring Multi-Dimensional Outcomes to Level of Functional Recovery after Traumatic Brain Injury.", "datePublished": "2022-06-24", "url": "https://questionsmedicales.fr/article/35607855", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1089/neu.2022.0013" } }, { "@type": "ScholarlyArticle", "name": "Functional recovery after total hip/knee replacement in obese people: A systematic review.", "datePublished": "2022-11-29", "url": "https://questionsmedicales.fr/article/36459889", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.rehab.2022.101710" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Actions chimiques et utilisations", "item": "https://questionsmedicales.fr/mesh/D020164" }, { "@type": "ListItem", "position": 3, "name": "Actions pharmacologiques", "item": "https://questionsmedicales.fr/mesh/D020228" }, { "@type": "ListItem", "position": 4, "name": "Mécanismes moléculaires de l'action pharmacologique", "item": "https://questionsmedicales.fr/mesh/D045504" }, { "@type": "ListItem", "position": 5, "name": "Inducteurs des enzymes du cytochrome P-450", "item": "https://questionsmedicales.fr/mesh/D065693" }, { "@type": "ListItem", "position": 6, "name": "Inducteurs du cytochrome P-450 CYP2C9", "item": "https://questionsmedicales.fr/mesh/D065698" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Inducteurs du cytochrome P-450 CYP2C9 - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Inducteurs du cytochrome P-450 CYP2C9", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-16", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Inducteurs du cytochrome P-450 CYP2C9", "description": "Comment identifier un inducteur du CYP2C9 ?\nQuels tests sont utilisés pour évaluer l'activité du CYP2C9 ?\nQuels signes indiquent une induction du CYP2C9 ?\nComment les interactions médicamenteuses sont-elles diagnostiquées ?\nQuels médicaments sont souvent des inducteurs du CYP2C9 ?", "url": "https://questionsmedicales.fr/mesh/D065698?mesh_terms=Recovery+of+Function&page=3#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Inducteurs du cytochrome P-450 CYP2C9", "description": "Quels symptômes peuvent indiquer une induction du CYP2C9 ?\nComment l'induction du CYP2C9 affecte-t-elle les médicaments ?\nQuels effets secondaires peuvent survenir ?\nLes symptômes varient-ils selon les patients ?\nQuels signes cliniques sont observés ?", "url": "https://questionsmedicales.fr/mesh/D065698?mesh_terms=Recovery+of+Function&page=3#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Inducteurs du cytochrome P-450 CYP2C9", "description": "Comment prévenir l'induction du CYP2C9 ?\nLes patients doivent-ils informer leur médecin des médicaments ?\nDes tests génétiques peuvent-ils aider à la prévention ?\nComment éduquer les patients sur les inducteurs ?\nLes changements de mode de vie peuvent-ils aider ?", "url": "https://questionsmedicales.fr/mesh/D065698?mesh_terms=Recovery+of+Function&page=3#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Inducteurs du cytochrome P-450 CYP2C9", "description": "Comment ajuster le traitement en cas d'induction du CYP2C9 ?\nQuels médicaments peuvent être utilisés pour contrer l'induction ?\nComment surveiller l'efficacité du traitement ?\nQuels sont les risques d'un traitement inapproprié ?\nLes changements de traitement doivent-ils être rapides ?", "url": "https://questionsmedicales.fr/mesh/D065698?mesh_terms=Recovery+of+Function&page=3#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Inducteurs du cytochrome P-450 CYP2C9", "description": "Quelles complications peuvent résulter de l'induction du CYP2C9 ?\nComment l'induction affecte-t-elle la santé globale ?\nLes complications sont-elles réversibles ?\nQuels sont les risques à long terme ?\nComment gérer les complications liées à l'induction ?", "url": "https://questionsmedicales.fr/mesh/D065698?mesh_terms=Recovery+of+Function&page=3#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Inducteurs du cytochrome P-450 CYP2C9", "description": "Quels sont les principaux facteurs de risque d'induction ?\nLa génétique joue-t-elle un rôle dans l'induction ?\nLes habitudes alimentaires influencent-elles l'induction ?\nLes maladies hépatiques augmentent-elles le risque ?\nLes interactions médicamenteuses sont-elles un facteur de risque ?", "url": "https://questionsmedicales.fr/mesh/D065698?mesh_terms=Recovery+of+Function&page=3#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment identifier un inducteur du CYP2C9 ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "L'identification se fait par l'analyse des antécédents médicamenteux et des tests de métabolisme." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour évaluer l'activité du CYP2C9 ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests de pharmacogénétique et des dosages de médicaments peuvent être utilisés." } }, { "@type": "Question", "name": "Quels signes indiquent une induction du CYP2C9 ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Une diminution de l'efficacité des médicaments métabolisés par CYP2C9 peut être un signe." } }, { "@type": "Question", "name": "Comment les interactions médicamenteuses sont-elles diagnostiquées ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Elles sont diagnostiquées par l'examen des interactions dans les bases de données médicales." } }, { "@type": "Question", "name": "Quels médicaments sont souvent des inducteurs du CYP2C9 ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Des médicaments comme la rifampicine et certains anticonvulsivants sont des inducteurs." } }, { "@type": "Question", "name": "Quels symptômes peuvent indiquer une induction du CYP2C9 ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes de sous-dosage des médicaments, comme une douleur persistante, peuvent apparaître." } }, { "@type": "Question", "name": "Comment l'induction du CYP2C9 affecte-t-elle les médicaments ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Elle peut réduire l'efficacité des médicaments, entraînant des symptômes de la maladie sous-jacente." } }, { "@type": "Question", "name": "Quels effets secondaires peuvent survenir ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Des effets secondaires liés à un sous-dosage, comme des convulsions, peuvent survenir." } }, { "@type": "Question", "name": "Les symptômes varient-ils selon les patients ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les symptômes peuvent varier en fonction de la génétique et des médicaments pris." } }, { "@type": "Question", "name": "Quels signes cliniques sont observés ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Des signes cliniques comme une réponse insuffisante au traitement peuvent être observés." } }, { "@type": "Question", "name": "Comment prévenir l'induction du CYP2C9 ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Éviter les inducteurs connus et surveiller les interactions médicamenteuses est essentiel." } }, { "@type": "Question", "name": "Les patients doivent-ils informer leur médecin des médicaments ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, informer le médecin de tous les médicaments pris aide à prévenir les interactions." } }, { "@type": "Question", "name": "Des tests génétiques peuvent-ils aider à la prévention ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des tests génétiques peuvent identifier les patients à risque d'induction enzymatique." } }, { "@type": "Question", "name": "Comment éduquer les patients sur les inducteurs ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "L'éducation sur les médicaments inducteurs et leurs effets est cruciale pour la prévention." } }, { "@type": "Question", "name": "Les changements de mode de vie peuvent-ils aider ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des changements de mode de vie, comme une alimentation saine, peuvent aider." } }, { "@type": "Question", "name": "Comment ajuster le traitement en cas d'induction du CYP2C9 ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Il peut être nécessaire d'augmenter la dose des médicaments affectés pour compenser." } }, { "@type": "Question", "name": "Quels médicaments peuvent être utilisés pour contrer l'induction ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Des inhibiteurs du CYP2C9 peuvent être utilisés pour réduire l'induction enzymatique." } }, { "@type": "Question", "name": "Comment surveiller l'efficacité du traitement ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "La surveillance se fait par des tests réguliers des niveaux de médicaments dans le sang." } }, { "@type": "Question", "name": "Quels sont les risques d'un traitement inapproprié ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Un traitement inapproprié peut entraîner des complications graves, comme des crises épileptiques." } }, { "@type": "Question", "name": "Les changements de traitement doivent-ils être rapides ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Les changements doivent être faits prudemment pour éviter des effets indésirables." } }, { "@type": "Question", "name": "Quelles complications peuvent résulter de l'induction du CYP2C9 ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications comme des crises convulsives ou une résistance au traitement peuvent survenir." } }, { "@type": "Question", "name": "Comment l'induction affecte-t-elle la santé globale ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Elle peut compromettre la santé en rendant les traitements moins efficaces, aggravant les maladies." } }, { "@type": "Question", "name": "Les complications sont-elles réversibles ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être réversibles avec un ajustement approprié du traitement." } }, { "@type": "Question", "name": "Quels sont les risques à long terme ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Les risques à long terme incluent des maladies chroniques dues à un traitement inefficace." } }, { "@type": "Question", "name": "Comment gérer les complications liées à l'induction ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "La gestion implique un suivi régulier et des ajustements de traitement basés sur les symptômes." } }, { "@type": "Question", "name": "Quels sont les principaux facteurs de risque d'induction ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent l'utilisation de certains médicaments, l'alcool et des maladies hépatiques." } }, { "@type": "Question", "name": "La génétique joue-t-elle un rôle dans l'induction ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des variations génétiques peuvent influencer l'activité du CYP2C9 et son induction." } }, { "@type": "Question", "name": "Les habitudes alimentaires influencent-elles l'induction ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Certaines habitudes alimentaires, comme la consommation de pamplemousse, peuvent influencer l'induction." } }, { "@type": "Question", "name": "Les maladies hépatiques augmentent-elles le risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les maladies hépatiques peuvent augmenter le risque d'induction du CYP2C9." } }, { "@type": "Question", "name": "Les interactions médicamenteuses sont-elles un facteur de risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les interactions entre médicaments peuvent augmenter le risque d'induction enzymatique." } } ] } ] }

Sources (10000 au total)

Potentially inappropriate medications are negatively associated with functional recovery in patients with sarcopenia after stroke.

Evidence is scarce for potentially inappropriate medications (PIMs) in rehabilitation medicine.... To examine the effect of PIMs on functional recovery in older patients with sarcopenia after stroke.... We conducted a retrospective cohort study in a post-acute rehabilitation hospital. All patients diagnosed with sarcopenia aged ≥ 65 years among all post-stroke patients hospitalized from 2015 to 2020 ... Of the eligible patients, 361 were 65 years or older, of whom 196 (mean age 81.0 years, 44.4% male) presented with sarcopenia and were included in the analysis. Of these, 131 (66.8%) were prescribed P... High admission PIMs prescription numbers are negatively associated with favorable discharge functional status and muscle strength in older patients with sarcopenia after stroke....

Functional recovery after total hip/knee replacement in obese people: A systematic review.

Several studies have investigated the influence of body mass index (BMI) on functional gain after total hip replacement (THR) or total knee replacement (TKR) in osteoarthritis, with contradictory resu... The study was registered with PROSPERO and conducted according to the PRISMA guidelines. A systematic literature search was conducted across Medline and EMBASE databases for articles published between... Twenty-six articles reporting on 68,840 persons (34,955 for THR and 33,885 for TKR) were included in the final analysis: 5 case-control studies, 21 cohort studies (9 for THR only, 10 for TKR only and ... Although there is a paucity of high-quality evidence, our findings show substantial functional gains in people with obesity after total joint replacement. Functional recovery after THR or TKR does not... CRD42018112919....

Effect of accelerated rehabilitation combined with enteral nutrition on gastrointestinal function recovery after hepatectomy.

To investigate the effect of accelerated rehabilitation combined with enteral nutrition on the recovery of gastrointestinal function in patients after hepatectomy.... In this prospective randomized controlled study, a total of 108 patients with liver cancer who underwent hepatectomy in our hospital from November 2020 to December 2021 were selected as the research s... The gastrointestinal function of patients in research group was significantly better than that in control group (P < 0.05). After intervention, the albumin (ALB) in research group was significantly hi... Accelerated rehabilitation combined with enteral nutrition can effectively restore the gastrointestinal function of patients after hepatectomy, which is worthy of clinical promotion....

Reduced trunk muscle mass in patients with stroke is associated with reduced balance function recovery.

Skeletal muscles are essential for postural retention and balance function. However, the relationship between trunk muscle mass (TMM) and balance function has not yet been clarified. This study aimed ... This retrospective observational study included patients aged ≥65 years with cerebral infarction admitted to our rehabilitation hospital from May 2018 to July 2022. The trunk muscle mass index (TMI) w... A total of 315 patients (mean age, 78.9 ± 8.0 years; 172 men and 143 women) were included. The median TMI was 7.31 kg/m... Reduced TMM negatively influences balance function recovery in patients after stroke. A strategy aimed at increasing TMM could have beneficial effects on balance function....